作者:金杜律师事务所 King & Wood Mallesons
2016年10月28日,华润医药集团有限公司(简称“华润医药”, 股票代码:3320) 在金杜律师事务所协助下正式在香港联交所主板上市。华润医药本次全球共发行15.43亿股,每股发行价为9.10港元,总募资金净额约为136.71亿港元,成为2016年港股市场最大非金融类IPO。如后续全额执行超额配售选择权,将成为有史以来最大中资医药IPO、全球排名第六位的医药类IPO。
On 28 October 2016, China Resources Pharmaceutical Group Ltd. (“CR Pharmaceutical”, stock code: 3320) had its H shares listed on the main board of the Hong Kong Stock Exchange, with King & Wood Mallesons (KWM) advising its underwriters. CR Pharmaceutical issued a total of 1.543 billion

MiFID II will introduce a comprehensive regulatory regime governing direct electronic access (DEA) to trading venues (regulated markets, multilateral trading facilities and organised trading facilities).




